# US 2024/0197880 A1 · New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197880 A1
- Document ID: US20240197880A1
- Status: Published application
- Kind: A1
- Application number: 18/556,957
- Filed: 2022-04-29
- Published: 2024-06-20
- Earliest claimed: 2021-04-30
- Applicants: Cellectis S.A.
- Inventors: Beatriz ARANDA-ORGILLES; Tomasz KURCON; Laurent POIROT
- Web page: https://patentgrep.com/patent/US20240197880A1

## CPC

- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/3092: {against tumour-associated mucins}
- C12N 5/0636: {T lymphocytes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/907: {in mammalian cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/49: Breast
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2501/2302: Interleukin-2 (IL-2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to genetically engineered immune cells expressing new anti-MUC1 chimeric antigen receptors and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.

## Claims

### Claim at position 1

1-77. (canceled)

### Claim 78

A method for manufacturing a population of engineered therapeutic immune cells, comprising the steps of:
a) providing immune cells originating from a patient or donor;
b) expressing in said cells an anti-MUC1 chimeric antigen receptor (CAR);
c) introducing at least one genetic modification(s) in the genome of said cell, said modification(s) being selected from those leading to an enhanced IL-2, IL-12, IL-15 or IL-18 expression;
d) expanding said cells to form a population of therapeutically effective immune cells.

### Claim 79 (depends on 78)

The method of claim 78, wherein further genetic modification(s) is introduced into the genome leading to:
reduced or inactivated TCR expression;
reduced or inactivated B2M;
reduced interaction between TGFβ and TGFβR2; and/or
reduced interaction between PD1 and PDL1;

### Claim 80 (depends on 79)

The method of claim 79, wherein said further genetic modification leads to the inactivation of the expression of at least one TGFbeta receptor.

### Claim 81 (depends on 78)

The method of claim 78, wherein said genetic modification(s) is (are) obtained by using sequence specific gene editing reagents.

### Claim 82 (depends on 78)

An engineered immune cell expressing an anti-MUC1 CAR obtainable by the method of claim 78.

### Claim 83

An engineered immune cell expressing an anti-MUC1 CAR, wherein said anti-MUC1 CAR comprises at least:
an extracellular ligand binding-domain comprising VH and VL from a monoclonal antibody targeting tMUC1 epitope(s);
a transmembrane domain; and
a cytoplasmic domain comprising a CD3 zeta signalling domain and a co-stimulatory domain,
wherein said extra cellular ligand binding-domain is directed against an antigen of the MUC1 polypeptide region HGVTSAPDTRPAPGSTAPPA (SEQ ID NO:1), and
wherein said CAR is co-expressed with another exogenous sequence encoding a cytokine selected from IL-2, IL-12, IL-15 and IL-18.

### Claim 84 (depends on 83)

The engineered immune cell of claim 83, wherein said engineered immune cell comprises at least one further genetic modification introduced into the genome leading to:
reduced or inactivated TCR expression;
reduced or inactivated B2M;
reduced interaction between TGFβ and TGFβR2; and/or
reduced interaction between PD1 and PDL1.

### Claim 85 (depends on 83)

The engineered immune cell of claim 83, wherein said anti-MUC1 comprises an extra cellular ligand binding-domain ScFvs having at least 95% sequence identity with respectively MUC1-A ScFv (SEQ ID NO:17), MUC1-B (SEQ ID NO:27), MUC1-C(SEQ ID NO:37), and/or MUC1-D (SEQ ID NO:47).

### Claim 86 (depends on 83)

The engineered immune cell of claim 83, wherein:
said variable light (VL) chain comprises CDRs selected from SEQ ID NO:11 (CDR-VL1-A), SEQ ID NO:12 (CDR-VL2-A) and SEQ ID NO:13 (CDR-VL3-A), and
said variable heavy (VH) chain comprises CDRs selected from SEQ ID NO:14 (CDR-VH1-A), SEQ ID NO:15 (CDR-VH2-A) and SEQ ID NO:16 (CDR-VH3-A).

### Claim 87 (depends on 83)

The engineered immune cell of claim 83, wherein said anti-MUC1 has at least 80% overall amino acid sequence identity with SEQ ID NO:18 (CLS MUC1-A CAR).

### Claim 88 (depends on 83)

The engineered immune cell of claim 83, wherein:
said variable light (VL) chain comprises CDRs selected from SEQ ID NO:21 (CDR-VL1-B), SEQ ID NO:22 (CDR-VL2-B) and SEQ ID NO:23 (CDR-VL3-B), and
said variable heavy (VH) chain comprises CDRs selected from SEQ ID NO:24 (CDR-VH1-B), SEQ ID NO:25 (CDR-VH2-B) and SEQ ID NO:26 (CDR-VH3-B).

### Claim 89 (depends on 83)

The engineered immune cell of claim 83, wherein said anti-MUC1 has at least 80% overall amino acid sequence identity with SEQ ID NO:28 (CLS MUC1-B CAR).

### Claim 90 (depends on 83)

The engineered immune cell of claim 83, wherein:
said variable light (VL) chain comprises CDRs selected from SEQ ID NO: 31(CDR-VL1-C), SEQ ID NO:32 (CDR-VL2-C) and SEQ ID NO:33 (CDR-VL3-C), and
said variable heavy (VH) chain comprises CDRs selected from SEQ ID NO:34 (CDR-VH1-C), SEQ ID NO:35 (CDR-VH2-C) and SEQ ID NO:36 (CDR-VH3-C).

### Claim 91 (depends on 83)

The engineered immune cell of claim 83, wherein said CAR has at least 80% overall amino acid sequence identity with SEQ ID NO:38 (CLS MUC1-C CAR).

### Claim 92 (depends on 83)

The engineered immune cell of claim 83, wherein:
said variable light (VL) chain comprising CDRs selected from SEQ ID NO:41 (CDR-VL1-D), SEQ ID NO:42 (CDR-VL2-D) and SEQ ID NO:43 (CDR-VL3-D), and
said variable heavy (VH) chain comprising CDRs selected from SEQ ID NO:44 (CDR-VH1-D), SEQ ID NO:45 (CDR-VH2-D) and SEQ ID NO:46 (CDR-VH3-D).

### Claim 93 (depends on 83)

The engineered immune cell of claim 83, wherein said CAR has at least 80% overall amino acid sequence identity with SEQ ID NO:48 (MUC1-D CAR).

### Claim 94 (depends on 83)

The engineered immune cell of claim 83, wherein said immune cell is T-cell or NK cell.

### Claim 95 (depends on 83)

A population of cells comprising more than 25% of engineered immune cells of claim 83.

### Claim 96 (depends on 95)

A therapeutic composition comprising the population of cells of claim 95.

### Claim 97 (depends on 95)

A method comprising administering the population of cells of claim 95 to a cancer patient.
